Richard N. Kender

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Whitehouse Station, NJ
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Thomas J. DesRosier, Attorney-in-Fact for Richard N. Kender
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Richard N. Kender

Form 4 holding Director

BICYCLE THERAPEUTICS PLC

Security class
Ordinary Shares
Shares / value
23,000
Estimated value
$570,860
Report date
02 Jan 2025
Price
$24.82
Ownership
Direct
Form 4 holding Director

Omega Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
50,000
Estimated value
Report date
20 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Interim Chief Executive Officer, Director

Seres Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
50,000
Estimated value
Report date
08 Jul 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

BICYCLE THERAPEUTICS PLC

Security class
Stock Option (right to buy)
Shares / value
12,500
Estimated value
Report date
02 Jan 2025
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount

Insider Reports Filed by Richard N. Kender

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .